Dren Bio 完成 3.5 亿美元融资，推进 dibotatug 后期临床开发
Dren Bio raises $350m for dibotatug clinical development
Dren Bio 完成 3.5 亿美元超额认购私募融资，用于推进其核心在研疗法 dibotatug（DR-01）的后期临床评估、监管申报及潜在商业化。dibotatug 为靶向 CD94 的全人源单克隆抗体，正在 Phase I/II 试验中评估复发或难治性细胞毒性 T 细胞淋巴瘤和大颗粒淋巴细胞白血病，已有超过 300 人接受治疗。
Dren Bio will use the capital to progress its broader pipeline in autoimmune disorders, immunology, neurology, and oncology.
Dren Bio has secured $350m in an oversubscribed private financing round to advance its primary investigational therapy, dibotatug (DR-01), via late-stage clinical evaluation, regulatory submission, and potential commercialisation.
The privately held clinical-stage biotechnology company will also use the capital to progress its broader research pipeline in autoimmune disorders, immunology, neurology, and oncology.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Juvia Group and Lightspeed Venture Partners co-led the investment round.
Following the transaction, Juvia Group co-founder and managing director Sujal Shah and Lightspeed partner Shelley Chu have joined the Dren Bio Board of Directors.
Additional new participants included Cormorant Asset Management, General Catalyst, Mirae Asset Capital Life Science, and OrbiMed.
Existing investors 8VC, Aisling Capital, ArrowMark Partners, BVF Partners, HBM Healthcare Investments, Mission BioCapital, SR One, and Taiho Ventures also contributed capital.
Dibotatug is a fully human monoclonal antibody engineered to bind cluster of differentiation 94 (CD94). The therapy selectively removes disease-causing cytotoxic cells whilst sparing the wider immune system.
The company’s furthest advanced clinical programmes focus on cytotoxic T-cell lymphoma, an aggressive haematologic malignancy, and large granular lymphocytic leukaemia, a chronic condition associated with severe neutropenia, anaemia, and transfusion requirements.
Neither disease currently has approved therapeutic options.
More than 300 individuals have received treatment in an ongoing Phase I/II trial evaluating dibotatug for relapsed or refractory forms of both conditions.
Dren Bio plans to expand clinical testing of dibotatug into aplastic anaemia, other bone marrow failure syndromes, and autoimmune indications.
Dren Bio CEO and founder Nenad Tomasevic said: “We founded Dren Bio with a simple vision: pursue novel science to develop medicines that meaningfully improve the lives of patients with devastating diseases and few treatment options.
“Seeing dibotatug advance to this late stage of development, alongside a clinically validated platform that continues to generate promising new therapies, is deeply gratifying and reflects the vision that inspired us from day one.”
In July 2024, Dren Bio partnered with Novartis subsidiary Novartis Pharma to discover and develop therapeutic bispecific antibodies to treat cancer.
来源：Pharmaceutical Technology · pharmaceutical-technology.com